Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2013

View Archived Issues

Neumedicines receives BARDA intent to exercise contract option on HemaMax

Researchers prepare neuraminidase inhibitor prodrug for influenza

PI3Kdelta inhibition delays the progression of autoimmune diabetes

Eisai profiles progress of fiscal 2012

Fluorinated enigmol analogues demonstrate oncolytic activity in vivo

Researchers present first PET radiotracers targeting SV2

New antimicrobial development strategy to minimize acquired drug resistance

AstraZeneca designs matched triplicate approach for optimization of drug pharmacokinetics

Dosing completed in phase I TTI-1612 study

Aridis Pharmaceuticals acquires anti-infective MAb products from Kenta Biotech

Northwest Biotherapeutics begins phase III DCVax-L brain cancer trial in Europe

Daiichi Sankyo highlights progress of fiscal 2012

Merck & Co. discloses new GPR131 receptor agonists

A novel mGlur5PV-/- mouse model of schizophrenia shows altered sensorimotor gating

Merck & Co. prepares novel orexin receptor antagonists

New ROMK blockers disclosed by Merck & Co.

DBV Technologies and Stallergenes collaborate on respiratory allergy therapy

Allergan divulges novel FPRL1 ligands

SciClone and Zensun sign licensing agreement for Chinese rights to Neucardin

Researchers at Merck Frosst Canada patent new agents for HIV infection

RuiYi and Genor BioPharma sign agreement for anti-IL-6 antibody in China

Roche prepares new CB2 receptor agonists

Bayer to acquire Steigerwald

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...